{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:47:49Z","timestamp":1793152069640,"version":"4.5.0"},"reference-count":154,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Tolentino Eye Research Foundation"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2022,10,3]]},"DOI":"10.1080\/13543784.2022.2113375","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T02:11:20Z","timestamp":1660356680000},"page":"1067-1085","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":33,"title":["Investigational drugs in clinical trials for macular degeneration"],"prefix":"10.1080","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4914-7356","authenticated-orcid":false,"given":"Michael J","family":"Tolentino","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Central Florida, Florida, USA"},{"name":"Blue Ocean Clinical Research, Lakeland, Florida, USA"},{"name":"Aviceda Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Tolentino","sequence":"additional","affiliation":[{"name":"Aviceda Therapeutics, Cambridge, Massachusetts, USA"},{"name":"Department of Biology, University of California Berkeley, Berkeley, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.041"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2017.1401646"},{"issue":"3","key":"cit0003","first-page":"82","volume":"158","author":"Pinelli R","year":"2020","journal-title":"Arch Ital Biol"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.08.038"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S246245"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2021.01.009"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-13034"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120824"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.10.1417"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169531"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108391"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2020.03.012"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-66014-7_5"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M084442"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8657"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.14.7.835"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03796-9"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1755"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201751"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.4.1971"},{"issue":"1","key":"cit0021","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4049\/jimmunol.122.1.75","volume":"122","author":"Kazatchkine MD","year":"1979","journal-title":"J Immunol"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1021\/bi4003452"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-680009"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2418-4"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.01.036"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.05.016"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.16.1793"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1159\/000094141"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-3064"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1021\/bi700459a"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2014.11.005"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4853"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2018.03.013"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA117.001278"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.669226"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.6546-10.2011"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1990.86"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1038\/nature10449"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M305460200"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.222551899"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1021\/tx200206v"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106421"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.305925"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2011.02695.x"},{"key":"cit0045","first-page":"503725","volume":"2013","author":"Cruz-Guilloty F","year":"2013","journal-title":"Int J Inflam"},{"key":"cit0046","first-page":"679","volume":"26","author":"Jiao H","year":"2020","journal-title":"Mol Vis"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110647"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14716"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.03.002"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2012.06.010"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-0631-0_6"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2014.12.045"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2020.01.008"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23945"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155494"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-018-0278-0"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1038\/srep30933"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23757"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25878"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13362"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.0010"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.19-26882"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13886"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1172\/JCI44490"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2012.0407"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-505-7_30"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1012512"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.06.034"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2013.12.034"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2012.12.001"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-013-9621-3"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-23892"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0097"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606627"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03288-x"},{"issue":"5","key":"cit0076","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1055\/s-0043-105138","volume":"234","author":"Langmann T","year":"2017","journal-title":"Klin Monbl Augenheilkd"},{"key":"cit0077","unstructured":"Healthcare G. The dominance of eylea is expected to persist in the foreseeable future pharmaceutical technology2021 [updated 2021 Dec 1]. Available from: https:\/\/www.pharmaceutical-technology.com\/comment\/eylea-bayer-regeneron\/"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.028"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.017"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420975303"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.1.78"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100130062010"},{"key":"cit0084","unstructured":"Therapeutics O. ONS-5010\/LYTENAVA\u2122 OVERVIEW. Available from: https:\/\/outlooktherapeutics.com\/lytenava-overview\/"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.03.045"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.01.029"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305149"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.1544"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.712572"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.3390\/jcm4010172"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.044"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.03.059"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10050"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318265801d"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(03)00356-7"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.08.015"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-009-1081-y"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.036"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01830-5"},{"key":"cit0102","author":"Baker-Schena L","year":"2019","journal-title":"EyeNet Magazine"},{"key":"cit0103","volume-title":"Key takeaways from the RGX-314 phase I\/IIa clinical trial for wet AMD (Cohorts 1-5)","author":"Heier J"},{"key":"cit0104","unstructured":"Khanani AM. Retina society. 2021 Sept 29 https:\/\/ocutx.gcs-web.com\/static-files\/3c59d3b0-9995-4e63-a972-e233a7550b1b; Chicago, IL2021"},{"key":"cit0105","unstructured":"ABC Platform. Available from: https:\/\/kodiak.com\/our-science\/"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211027708"},{"key":"cit0107","unstructured":"A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD) [Internet]. 2017. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03345082."},{"key":"cit0108","volume-title":"Phase 2b clinical results of OPT-302 (VEGF-C\/D \u2018Trap\u2019) combination treatment in nAMD","author":"Baldwin M","year":"2019"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.08.026"},{"key":"cit0110","unstructured":"Efficacy and safety trial of conbercept intravitreal injection for neovascular age-related macular degeneration (PANDA-1). 2020."},{"key":"cit0111","volume-title":"Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference","author":"Rahal FM"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.03.003"},{"key":"cit0113","unstructured":"A proof-of-concept study of Faricimab (RO6867461) in participants with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) ClinicalTrials.gov.2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02484690."},{"key":"cit0114","unstructured":"Study to evaluate faricimab (RO6867461; RG7716) for extended durability in the treatment of neovascular age related macular degeneration (nAMD) ClinicalTrials.gov2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03038880."},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"cit0116","unstructured":"Asclepix. AXT107. Available from: https:\/\/asclepix.com\/technology\/"},{"key":"cit0117","unstructured":"Safety and bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (SHASTA) 2021 [updated 2021 Mar 24]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04746963"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2016.02.004"},{"key":"cit0119","unstructured":"Innovent announces the results of the phase ib clinical trial of IBI302, a first-in-class anti-vegf and anti-complement bi-specific fusion protein for neovascular age-related macular degeneration at 2021 american academy of ophthalmology [Internet]. CISION PR Newswire; Nov 14, 2021"},{"key":"cit0120","volume-title":"Hawaiian Eye & Retina Annual Meeting","author":"Boyer DS","year":"2019"},{"key":"cit0121","unstructured":"Graybug vision reports full-data analysis from 12-month treatment phase of ALTISSIMO phase 2b trial in wet AMD [Internet]; May 12, 2021. Available from: https:\/\/investors.graybug.vision\/news-releases\/news-release-details\/graybug-vision-reports-full-data-analysis-12-month-treatment"},{"key":"cit0122","volume-title":"Ophthalmology Innovation Summit at the American Academy of Ophthalmology annual meeting (OIS@AAO)","author":"Chaney P","year":"2019"},{"key":"cit0123","unstructured":"BIOMEDICAL C. CLEARSIDE biomedical corporate overview. Available from: https:\/\/clearsidebio.com\/about\/"},{"key":"cit0124","unstructured":"BIOMEDICAL C. OASIS phase 1\/2a clinical trial safety results 2021 [updated 2021 Dec 21]. Available from: https:\/\/ir.clearsidebio.com\/static-files\/73cbcd76-02e8-472b-88dd-c8985318c66e"},{"key":"cit0125","unstructured":"Kaiser E New sustained-release anti-VEGF formulation EYP-1901 proves safe, effective in phase 1 trials. Ophthalmology Times. 2021."},{"key":"cit0126","unstructured":"Therapeutix O OTX-TKI sustained-release product candidate for retinal diseases. Available from: https:\/\/www.ocutx.com\/research\/otx-tki\/"},{"key":"cit0127","volume-title":"ARVO Annual Meeting","author":"Wong JG","year":"2021"},{"issue":"5","key":"cit0128","volume":"49","author":"John AW","year":"2018","journal-title":"OSLI Retina"},{"key":"cit0129","first-page":"3766","volume":"58","author":"BG GCR","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0130","unstructured":"Open-label study of intravitreal ICON-1 in patients with choroidal neovascularization secondary to age-related macular degeneration (AMD) Clinicaltrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03452527"},{"key":"cit0131","unstructured":"E J. AKST4290: an oral small molecule CCR3 antagonist. Ophthamology Innovation Summit; July 25,2019; Chicago, IL2019."},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2019.1673368"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.02.025"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.02.031"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.08.027"},{"key":"cit0136","first-page":"4305","volume":"61","author":"McCaleb GJJJSSFRSGESM","year":"2020","journal-title":"Investigative Ophthalmology And Visual Science"},{"key":"cit0137","volume-title":"Interim results from a first-in- human phase I\/II gene therapy study (FOCUS) of GT005, an investigational AAV2 Vector encoding Complement Factor I (CFI), in patients with Geographic Atrophy (GA)","author":"Kiss S","year":"2021"},{"key":"cit0138","unstructured":"Therapeutics G. Gemini therapeutics announces initial data from its ongoing phase 2a study of GEM103 in patients with geographic atrophy secondary to dry age-related macular degeneration [cited 2021 Jun 22]. Available from: https:\/\/investors.geminitherapeutics.com\/news\/news-details\/2021\/Gemini-Therapeutics-Announces-Initial-Data-From-Its-Ongoing-Phase-2a-Study-of-GEM103-in-Patients-With-Geographic-Atrophy-Secondary-to-Dry-Age-Related-Macular-Degeneration\/default.aspx"},{"key":"cit0139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.06.017"},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10199-2"},{"key":"cit0141","first-page":"361","volume":"60","author":"Allingham MJ","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0142","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.178657"},{"key":"cit0143","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1448060"},{"key":"cit0144","unstructured":"Cell L. OpRegen for dry AMD. Available from: https:\/\/lineagecell.com\/products-pipeline\/opregen\/"},{"key":"cit0145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.04.006"},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.11.011"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.10.13"},{"key":"cit0148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.08.012"},{"key":"cit0149","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.07.042"},{"key":"cit0150","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.8.15"},{"key":"cit0151","doi-asserted-by":"publisher","DOI":"10.1007\/BF02150948"},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.1002\/glia.24073"},{"key":"cit0153","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2021.09.002"},{"key":"cit0154","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.12.5939-5947.1998"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2022.2113375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:06:17Z","timestamp":1676390777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2022.2113375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":154,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"alternative-id":["10.1080\/13543784.2022.2113375"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2022.2113375","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}